Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Aliment Pharmacol Ther ; 49(6): 664-680, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30735257

RESUMEN

BACKGROUND: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately. AIM: To cover the range of potential adverse reactions as a result of biologic therapy and specifically management of these events. METHODS: A Medline and Pubmed search was undertaken. Search terms included were "anti-TNF," "infliximab" or "adalimumab" or "golimumab" combined with the keywords "ulcerative colitis" or "Crohn's disease" or "inflammatory bowel disease" and then narrowed to articles containing the keywords "complications," "side effects" or "adverse events" or "safety profile." International guidelines were also reviewed where relevant. RESULTS: Adverse events discussed in this review include infusion reactions, blood disorders and infections (including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological and those linked to viral disease are discussed. CONCLUSIONS: Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients. Research advances are improving the understanding, recognition and management of these adverse events.


Asunto(s)
Adalimumab/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Manejo de la Enfermedad , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Infliximab/efectos adversos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab/uso terapéutico , Anemia/inducido químicamente , Anemia/metabolismo , Anticuerpos Monoclonales/uso terapéutico , Enfermedades Autoinmunes/inducido químicamente , Enfermedades Autoinmunes/metabolismo , Humanos , Enfermedades Inflamatorias del Intestino/metabolismo , Infliximab/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismo
2.
United European Gastroenterol J ; 7(2): 199-209, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-31080604

RESUMEN

Background: Endoscopy within 24 h of admission (early endoscopy) is a quality standard in acute upper gastrointestinal bleeding (AUGIB). We aimed to audit time to endoscopy outcomes and identify factors affecting delayed endoscopy (>24 h of admission). Methods: This prospective multicentre audit enrolled patients admitted with AUGIB who underwent inpatient endoscopy between November and December 2017. Analyses were performed to identify factors associated with delayed endoscopy, and to compare patient outcomes, including length of stay and mortality rates, between early and delayed endoscopy groups. Results: Across 348 patients from 20 centres, the median time to endoscopy was 21.2 h (IQR 12.0-35.7), comprising median admission to referral and referral to endoscopy times of 8.1 h (IQR 3.7-18.1) and 6.7 h (IQR 3.0-23.1), respectively. Early endoscopy was achieved in 58.9%, although this varied by centre (range: 31.0-87.5%, p = 0.002). On multivariable analysis, lower Glasgow-Blatchford score, delayed referral, admissions between 7:00 and 19:00 hours or via the emergency department were independent predictors of delayed endoscopy. Early endoscopy was associated with reduced length of stay (median difference 1 d; p = 0.004), but not 30-d mortality (p = 0.344). Conclusions: The majority of centres did not meet national standards for time to endoscopy. Strategic initiatives involving acute care services may be necessary to improve this outcome.


Asunto(s)
Endoscopía del Sistema Digestivo , Hemorragia Gastrointestinal/diagnóstico , Enfermedad Aguda , Anciano , Anciano de 80 o más Años , Diagnóstico Tardío , Endoscopía del Sistema Digestivo/métodos , Femenino , Hemorragia Gastrointestinal/etiología , Hospitalización , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Factores de Tiempo
3.
J Matern Fetal Neonatal Med ; 23(11): 1315-7, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20230314

RESUMEN

Serum calcium, 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in umbilical cord blood samples taken from 54 White and 22 South Asian babies born in the UK during the summer months. South Asians had lower serum calcium (p < 0.0027) and 25OHD (p < 0.0002) than Whites. Serum PTH was low in all subjects, but South Asians had relatively higher concentrations of serum PTH (p < 0.001) than Whites. The lower vitamin D and calcium in South Asian newborns is not associated with secondary hyperparathyroidism as previously reported but may still explain their increased prevalence of neonatal hypocalcaemia and rickets.


Asunto(s)
Pueblo Asiatico/estadística & datos numéricos , Sangre Fetal/química , Hormona Paratiroidea/sangre , Vitamina D/sangre , Población Blanca/estadística & datos numéricos , Adolescente , Adulto , Asia Sudoriental/etnología , Etnicidad/estadística & datos numéricos , Femenino , Sangre Fetal/metabolismo , Humanos , Recién Nacido , Hormona Paratiroidea/análisis , Hormona Paratiroidea/metabolismo , Embarazo , Reino Unido/epidemiología , Vitamina D/análisis , Vitamina D/metabolismo , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA